229 related articles for article (PubMed ID: 18502140)
1. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation.
Chou AH; Yeh TH; Ouyang P; Chen YL; Chen SY; Wang HL
Neurobiol Dis; 2008 Jul; 31(1):89-101. PubMed ID: 18502140
[TBL] [Abstract][Full Text] [Related]
2. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
3. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
[TBL] [Abstract][Full Text] [Related]
5. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
6. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
7. Neurodegenerative phosphoprotein signaling landscape in models of SCA3.
Sowa AS; Popova TG; Harmuth T; Weber JJ; Pereira Sena P; Schmidt J; Hübener-Schmid J; Schmidt T
Mol Brain; 2021 Mar; 14(1):57. PubMed ID: 33741019
[TBL] [Abstract][Full Text] [Related]
8. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
[TBL] [Abstract][Full Text] [Related]
9. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
[TBL] [Abstract][Full Text] [Related]
10. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP
PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231
[TBL] [Abstract][Full Text] [Related]
11. The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.
Koppenol R; Conceição A; Afonso IT; Afonso-Reis R; Costa RG; Tomé S; Teixeira D; da Silva JP; Côdesso JM; Brito DVC; Mendonça L; Marcelo A; Pereira de Almeida L; Matos CA; Nóbrega C
Brain; 2023 Jun; 146(6):2346-2363. PubMed ID: 36511898
[TBL] [Abstract][Full Text] [Related]
12. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
13. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript.
Ramani B; Harris GM; Huang R; Seki T; Murphy GG; Costa Mdo C; Fischer S; Saunders TL; Xia G; McEachin RC; Paulson HL
Hum Mol Genet; 2015 Mar; 24(5):1211-24. PubMed ID: 25320121
[TBL] [Abstract][Full Text] [Related]
14. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
16. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
[TBL] [Abstract][Full Text] [Related]
17. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone rescue cerebellar degeneration in SCA3 transgenic mice.
Wu S; Liu K; Cheng W; Su S; Lin Y; Lin T; Cheng Y; Chang J; Wu Y; Liu C
Biochem Biophys Res Commun; 2020 Aug; 529(2):467-473. PubMed ID: 32703453
[TBL] [Abstract][Full Text] [Related]
19. Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.
Bushart DD; Zalon AJ; Zhang H; Morrison LM; Guan Y; Paulson HL; Shakkottai VG; McLoughlin HS
Cerebellum; 2021 Feb; 20(1):41-53. PubMed ID: 32789747
[TBL] [Abstract][Full Text] [Related]
20. No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
Schöls L; Reimold M; Seidel K; Globas C; Brockmann K; Hauser TK; Auburger G; Bürk K; den Dunnen W; Reischl G; Korf HW; Brunt ER; Rüb U
Brain; 2015 Nov; 138(Pt 11):3316-26. PubMed ID: 26362908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
